Brian Druker
- Hematology top 0.01%
- Chronic Myeloid Leukemia Treatments 353
- Acute Myeloid Leukemia Research 101
- Genetics top 0.01%
- Chronic Lymphocytic Leukemia Research 272
- Myeloproliferative Neoplasms: Diagnosis and Treatment 59
- Rheumatology top 0.01%
- Eosinophilic Disorders and Syndromes 165
- Gastroenterology top 0.05%
- Oncology top 0.05%
- Cytokine Signaling Pathways and Interactions 34
-
- Acute Lymphoblastic Leukemia research 61
-
- Monoclonal and Polyclonal Antibodies Research 37
- Co-authors
- Elisabeth BuchdungerNicholas LydonMichael W. DeiningerRenaud CapdevilleMoshe TalpazCharles L. SawyersDebra RestaHagop M. Kantarjian
- Cited by
- HematologyGeneticsRheumatology
- Partner nations
- United StatesSwitzerlandGermany
In The Last Decade
Brian Druker
587 papers receiving 53.3k citations
Hit Papers
Peers
Comparison fields: 5 of 169
- Hematology 30.5k
- Genetics 21.7k
- Rheumatology 13.5k
- Gastroenterology 4.3k
- Oncology 10.9k
Countries citing papers authored by Brian Druker
This map shows the geographic impact of Brian Druker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Druker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Druker more than expected).
Fields of papers citing papers by Brian Druker
This network shows the impact of papers produced by Brian Druker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Druker. The network helps show where Brian Druker may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Brian Druker, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 5 | |
| 2 | 2021 | 6 | |
| 3 | 2020 | 17 | |
| 4 | 2019 | 17 | |
| 5 | 2019 | 222 | |
| 6 | 2018 | 37 | |
| 7 | 2016 | 26 | |
| 8 | 2016 | 96 | |
| 9 | 2015 | 17 | |
| 10 | 2015 | 128 | |
| 11 | 2014 | 86 | |
| 12 | 2014 | 103 | |
| 13 | 2013 | 23 | |
| 14 | 2012 | 100 | |
| 15 | 2011 | 77 | |
| 16 | Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS studybreakdown → | 2008 | 491 |
| 17 | 2007 | 160 | |
| 18 | 2006 | 151 | |
| 19 | 2006 | 23 | |
| 20 | In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutantsbreakdown → | 2005 | 812 |
About Brian Druker
Brian Druker is a scholar working on Hematology, Genetics and Rheumatology, having authored 607 papers that have together received 54.8k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (353 papers), Chronic Lymphocytic Leukemia Research (272 papers), Eosinophilic Disorders and Syndromes (165 papers), Acute Myeloid Leukemia Research (101 papers), Acute Lymphoblastic Leukemia research (61 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (59 papers), Monoclonal and Polyclonal Antibodies Research (37 papers) and Cytokine Signaling Pathways and Interactions (34 papers). The work is most often cited by research in Hematology (30.5k citations), Genetics (21.7k citations) and Rheumatology (13.5k citations). Brian Druker has collaborated with scholars based in United States, Switzerland and Germany. Frequent co-authors include Elisabeth Buchdunger, Nicholas Lydon, Michael W. Deininger, Renaud Capdeville, Moshe Talpaz, Charles L. Sawyers, Debra Resta, Hagop M. Kantarjian, J. Ford and Sayuri Ohno-Jones. Their work appears in journals such as Blood, Journal of Biological Chemistry, Leukemia, Cancer Research and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.